<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung DiseasePierre‐Antoine Juge, Annick Clément, Yaël A de Man et al.|New England Journal of Medicine|2018Cited by 501
Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer—clinical aspects and relationship with tumour response: a single-centre prospective cohort studyMarie Kostine, Thierry Schaeverbeke, L. Rouxel et al.|Annals of the Rheumatic Diseases|2017Cited by 302
OX40 Ligand Contributes to Human Lupus Pathogenesis by Promoting T Follicular Helper ResponseC. Jacquemin, Patrick Blanco, Nathalie Schmitt et al.|Immunity|2015Cited by 223
Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse eventsMarie Kostine, Thierry Schaeverbeke, Eleonora Mauric et al.|European Journal of Cancer|2021Cited by 93
OX40L/OX40 axis impairs follicular and natural Treg function in human SLEC. Jacquemin, Patrick Blanco, Jean‐François Augusto et al.|JCI Insight|2018Cited by 88